Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily esomeprazole for treatment of pediatric GERD (ages 1–11)
2004-002370-39Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Started Dec 2006; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2004-002370-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002370-39.